VPDiagnostics Gets $2.9M NIH Grant

Luke Timmerman3/4/09

Seattle-based VPDiagnostics has secured a $2.9 million grant from the National Institutes of Health to run a clinical trial of its MRI-based technology for determining whether patients are at high risk of stroke. The trial is expected to enroll about 300 patients, and will track them for 18 months, says Mike Hartmann, vice president of business and product development. The technology is based on more than 15 years of research at the University of Washington.

Luke Timmerman is the National Biotech Editor of Xconomy, and the Editor of Xconomy Seattle. E-mail him at ltimmerman@xconomy.com or follow him on Twitter at twitter.com/ldtimmerman.